Introduction: Women are more likely to develop SA than their male counterparts. This analysis examines sex differences in disease, biological phenotype and treatment from UKSAR.Methods: Data for patients meeting the ERS/ATS SA criteria in UKSAR (n=3,679) was analysed by sex using univariate and multivariate logistic regression analyses.Results: SA patients were predominantly female (60.9%). Women were more likely to be obese (OR 1.67, 95% CI: 145, 1.93) and to have uncontrolled disease on asthma control questionnaire 6 (OR 1.14, 95% CI: 1.09, 1.18), more likely to have exacerbations (OR 1.13, 95% CI: 1.10, 1.17) and report asthma hospital admissions (OR 1.46 95% CI: 1.26, 1.70). Lung function was better in women, with percent predicted FEV1 3.9% higher than their male counterparts. Women had lower mean IgE (129 vs 208 IU/mL, p<0.001)) and mean FeNO (36 vs 46ppm, p<0.001) type-2 biomarkers but no significant difference in blood eosinophils or biologic therapy. Women were less likely to be on long-term OCS (OR 0.86, 95% CI: 0.75, 0.99). Results are displayed in figure 1.Conclusion: Significant differences were seen between the characteristics of men and women with SA. Women had worse asthma control, increased exacerbations and obesity despite higher FEV1 percent predicted, lower FeNO and Total IgE compared with their male counterparts. Understanding these disparities is important to deliver personalised SA treatment.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 308.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).